Pharnext (CE) (PNEXF) Quote

Something weird with the ticker FINRA has vs how the stock is really trading "over there..." and, well, not trading "over here."

Here's the real history, and it's in Euros, but the PPS and volume is reflective of the last RS listed in FINRA:

https://finance.yahoo.com/quote/ALPHA.PA/history/

This tells me the US ticker is some sort of "dummy" and the real action, or rather major dilution, is happening over there.

PNEXF: another .0001 to one reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

how much time do you have?

Sign me up....it will be better than owning BRK.A. If they do a forward split I'll be rich I tell ya.

There it is... $25M PPS. You just know there's an "investor" with that asking price for 1 share just hoping it gets hit....

I'm surprised FINRA processed the splits because PNEXF is on the Expert Market for non-compliance to Rule 15c2-11

https://www.otcmarkets.com/stock/PNEXF/security

Agreed on the O/S....."Can’t be more than 2". Just wait for the MOASS

You’re right, I am.
Wonder what the O/S is. Can’t be more than 2.

Methinks yer off a zero.....$25,000,000 per share. But, who's counting, hahaha.

That’s what you call wiping out the legacy equity….

The fun part to watch will be opening at $2.5M per share.

PNEXF: yikes......effective Sept. 18,2023 another one for 5,000 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Holy crap. That’s, what. 1 - 50,000,000 since November?

PNEXF .0001 for one reverse split:


https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

PNEXF: effective Nov. 23,2022 a one for 5,000 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Thanks for sharing this info with us.

It's good to now, thanks.

Thanks for sharing this info with us.

What exactly do you want?

Developed over the last 30 years, this concept is a new paradigm recognized by internationally renowned scientists, including several Nobel laureates. PLEOTHERAPY differs from monotherapy, the principle of which is to target a single therapeutic target by allowing the treatment of several targets at the same time thanks to PLEODRUG ™ . These are low-dose, synergistic combinations of drugs already used for other diseases with a known safety profile, and many benefits: an excellent safety and efficacy profile as well as extensive and robust intellectual property. Moreover, the use of already approved molecules considerably reduces the duration and cost of development of a PLEODRUG compared to a conventional drug.

Pharnext's goal is to become the champion of repositioning and combinations. We have chosen, to demonstrate the relevance of this approach, to start working on diseases with high medical needs that have not received satisfactory treatment to date: Charcot-Marie-Tooth type 1A disease and Alzheimer.